- Home
- JSPR vs ENTX Comparison
JSPR vs ENTX Comparison
Compare JSPR & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- ENTX
- Stock Information
- Founded
- JSPR 2018
- ENTX 2010
- Country
- JSPR United States
- ENTX Israel
- Employees
- JSPR N/A
- ENTX N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JSPR Health Care
- ENTX Health Care
- Exchange
- JSPR Nasdaq
- ENTX Nasdaq
- Market Cap
- JSPR 85.8M
- ENTX 69.6M
- IPO Year
- JSPR N/A
- ENTX 2018
- Fundamental
- Price
- JSPR $4.73
- ENTX $2.38
- Analyst Decision
- JSPR Strong Buy
- ENTX Strong Buy
- Analyst Count
- JSPR 10
- ENTX 1
- Target Price
- JSPR $62.50
- ENTX $10.00
- AVG Volume (30 Days)
- JSPR 181.2K
- ENTX 46.1K
- Earning Date
- JSPR 05-13-2025
- ENTX 05-09-2025
- Dividend Yield
- JSPR N/A
- ENTX N/A
- EPS Growth
- JSPR N/A
- ENTX N/A
- EPS
- JSPR N/A
- ENTX N/A
- Revenue
- JSPR N/A
- ENTX $181,000.00
- Revenue This Year
- JSPR N/A
- ENTX N/A
- Revenue Next Year
- JSPR N/A
- ENTX N/A
- P/E Ratio
- JSPR N/A
- ENTX N/A
- Revenue Growth
- JSPR N/A
- ENTX N/A
- 52 Week Low
- JSPR $3.13
- ENTX $1.41
- 52 Week High
- JSPR $26.84
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- JSPR 53.34
- ENTX 76.72
- Support Level
- JSPR $3.87
- ENTX $1.50
- Resistance Level
- JSPR $4.99
- ENTX $1.84
- Average True Range (ATR)
- JSPR 0.40
- ENTX 0.15
- MACD
- JSPR 0.18
- ENTX 0.09
- Stochastic Oscillator
- JSPR 86.02
- ENTX 81.46
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.